Search Site

Search form

Current Press Releases

All Releases
View Summary Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017
Nov 7, 2016
PDF 66.2 KB
View Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 8
Nov 2, 2016
PDF 7.8 KB
View Summary Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF
Oct 27, 2016
PDF 74.5 KB
View Summary Vertex Reports Third Quarter 2016 Financial Results
Oct 25, 2016
PDF 45.0 KB
View Summary Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis
Oct 25, 2016
PDF 50.5 KB
View Summary Vertex to Announce Third Quarter 2016 Financial Results on October 25
Oct 7, 2016
PDF 7.9 KB
View Summary U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation
Sep 28, 2016
PDF 20.9 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Sep 9, 2016
PDF 8.0 KB
View Summary Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Aug 15, 2016
PDF 16.6 KB
View Summary Vertex Reports Second Quarter 2016 Financial Results
Jul 27, 2016
PDF 44.2 KB
View Summary Vertex to Announce Second Quarter 2016 Financial Results on July 27
Jul 14, 2016
PDF 8.1 KB
View Summary Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis
Jul 6, 2016
PDF 17.5 KB
View Summary Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference
Jun 10, 2016
PDF 21.7 KB
View Summary Vertex to Present at the Goldman Sachs Healthcare Conference on June 7
May 31, 2016
PDF 7.9 KB
View Summary U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation
May 31, 2016
PDF 17.1 KB
View Summary Vertex Reports First Quarter 2016 Financial Results
Apr 27, 2016
PDF 46.2 KB
View Summary Vertex to Announce First Quarter 2016 Financial Results on April 27
Apr 15, 2016
PDF 8.1 KB
View Summary Vertex to Present at the Barclays Healthcare Conference on March 15
Mar 10, 2016
PDF 7.9 KB
View Summary Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation
Mar 8, 2016
PDF 18.2 KB
View Summary Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Feb 24, 2016
PDF 16.4 KB
Showing 1-20 of 26 Page: 1 2  Next 20